This week, the U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S.
With this release, many ACDS members may begin receiving patient inquiries about the risk of adverse reactions to components in the vaccine. The American College of Allergy, Asthma and Immunology (ACAAI) recently released a statement with recommendations on guidance for physicians and other providers related to risk of an allergic reaction to the vaccination.
